



The weight-loss price wars are breaking Big Pharma’s business model
Subscribe to enjoy similar stories. Two years ago, a GLP-1 prescription could cost an uninsured patient more than $1,000 a month. Today, Novo Nordisk’s Wegovy pill starts at just $149 through cash-pay programs.
In the world of Big Pharma, this is unheard of. Typically, drug prices climb or plateau until generics arrive years later. That trend should be even stickier in a duopoly.
Yet the obesity market has turned traditional pharma economics upside down. As Leerink analyst David Risinger notes, there isn’t a comparable precedent for this level of price erosion in the industry’s history. This past week investors have seen the cost of this price war.
Novo Nordisk, maker of Wegovy and Ozempic, forecast a sharp sales decline for 2026, sending its stock down nearly 20% in the days that followed. The outlook for Eli Lilly, which makes Zepbound and Mounjaro, remains brighter, but only because a strong surge in volume is expected to offset the drag of recent price cuts. Eli Lilly’s outlook remains brighter, but only because a strong surge in volume is expected to offset the drag of recent price cuts.
Then on Thursday, shares of both companies fell sharply after Hims & Hers Health announced a $49-a-month compounded version of the Wegovy pill. They rebounded Friday after the Food and Drug Administration chief threatened action against the mass marketing of copycat drugs. The wild week for GLP-1 makers was a stark reminder of how unusual this market has become, operating more like a high-growth consumer business than a traditional drug market.
Read on livemint.com